Science Highlights 2024: Lung Cancer/Thoracic Malignancies

This session highlights six of the most clinically relevant abstracts within the Lung Cancers/Thoracic Malignancies track of the 2024 ASTRO Annual Meeting scientific program. These noteworthy scientific abstracts share important findings and feature cutting-edge research from leaders in the field. The Discussant compares and contrasts the current data to help you digest the latest science; places the study into context; and describes how the study can be put into clinical practice, if recommended. 

 
Highlighted abstracts include:

  • Phase ll Randomized Trial of Pirfenidone vs SOC therapy for RILI 

  • LU-005: Randomized Phase lll Concurrent and Adjuvant Atezo with C/RT for LS-SCLC 

  • ADRIATIC: Randomized Phase llll Adjuvant Durvalumab after C/RT for LS-SCLC 

  • Phase ll Trial of Concurrent and Adjuvant Durva with chemoradiation for LS-SCLC 

  • DART: Phase ll Trial Single agent Durvalumab + RT for poor performance status patients/non-chemoRT candidates with LA-NSCLC 

  • Phase lll Randomized Trial SIB versus conventional fractionation for LS-SCLC 

This activity is available from August 26, 2025 through 11:59 p.m. Eastern time on December 31, 2025. 

This activity was originally presented and recorded at the 2024 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists and radiation dosimetrists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss how different radiation and hormone therapy combinations affect quality of life and cancer control in patients with prostate cancer. 
  • Determine how newer technologies and shorter treatment schedules (like MRI-guided therapy and hypofractionation) can reduce side effects and improve patient comfort. 
  • Identify the best treatment plans based on patient needs, cancer risk, and long-term outcomes. 
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 0.50 Certificate of Attendance
    This activity was designated for 0.50 AMA PRA Category 1 Credit™.
Course opens: 
08/26/2025
Course expires: 
12/31/2025
Cost:
$79.00
Rating: 
0

Discussant: Inga Grills, MD 

Inga Grills, MD, is employed at William Beaumont University Hospital, Corewell Health and is on the Advisory Board for AstraZeneca. 

The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee and the 2024 ASTRO Annual Meeting Education and Steering Committees had control over the content of this activity. All relevant relationships have been mitigated.

Disclosure link: 
ASTRO Education Committee

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 0.50 Certificate of Attendance
    This activity was designated for 0.50 AMA PRA Category 1 Credit™.

Price

Cost:
$79.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the free member rate.

  • Nonmember: $79
  • Member: Free 

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until December 31, 2025, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.